WVXU: Companies are losing ground on DEI efforts

UC’s Littisha Bates guest speaker on Cincinnati Edition

WVXU’s Cincinnati Edition host Lucy May interviews Littisha Bates, PhD, UC’s associate dean for inclusive excellence and community partnerships, and Eric Ellis, president and CEO of Integrity Development Corp, on the current state of diversity, equity and inclusion initiatives since the death of George Floyd in 2020.

“That problems that existed before George Floyd are the same ones that exist after his murder,” Bates says in response to questions about the promises and initiatives made from corporations in 2020.

Bates says that while almost every company and employer moved to hire people into DEI roles, those roles have since lessened and even come under attack.  

A report, which prompted the panel interview, shows that inequity in the workplace is actually increasing, not decreasing. 

“There have been some changes,” Bates says, but not much ground has been gained. There is also new legislation in different states that could thwart future teachings about DEI, says Bates.

Dr. Bates is also faculty affiliate in UC's Department of Africana Studies.

Listen to the interview. 

Featured image at top by Andrew Higley/UC Marketing + Brand

Impact Lives Here

The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here

Related Stories

1

UC biologist talks about 'pearmageddon'

March 16, 2026

WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.

3

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.